Alpha Centric Advisors LLC Adaptimmune Therapeutics PLC Transaction History

Alpha Centric Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 25, 2022	SELL	$3.5 - $5.68 $239,750 - $389,080	-68,500 Closed	0 $0
Q3 2021 Mar 09, 2022	SELL	$3.44 - $6.37 $177,160 - $328,055	-51,500 Reduced 42.92%	68,500 $354,000
Q2 2021 Mar 09, 2022	BUY	$3.86 - $5.78 $266,340 - $398,820	69,000 Added 135.29%	120,000 $511,000
Q1 2021 Mar 09, 2022	BUY	$4.9 - $6.83 $34,300 - $47,810	7,000 Added 15.91%	51,000 $271,000
Q4 2020 Mar 11, 2022	BUY	$4.0 - $9.2 $159,200 - $366,160	39,800 Added 947.62%	44,000 $237,000
Q3 2020 Mar 11, 2022	BUY	$7.66 - $10.78 $18,384 - $25,872	2,400 Added 133.33%	4,200 $34,000
Q2 2020 Mar 11, 2022	BUY	$2.58 - $12.1 $4,644 - $21,780	1,800 New	1,800 $18,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $118M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.